Sorry, we were unable to verify the authenticity of this link. If you would like to proceed anyway, click the link below.

https://ccr.cancer.gov/news/article/mek-inhibitor-selumetinib-granted-breakthrough-designation-by-fda-to-treat-neurofibromatosis-type-one-in-pediatric-patients?cid=eb_govdel